Drug Profile


Alternative Names: BrdU; BrdUrd; BUdR; Neomark; NSC 38297

Latest Information Update: 19 Oct 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Cancer Institute (USA)
  • Developer INSYS Therapeutics, Inc; National Cancer Institute (USA)
  • Class Antineoplastics; Antivirals; Diagnostic agents; Pyrimidine nucleosides; Radiation-sensitising agents; Radiosensitisers; Small molecules
  • Mechanism of Action Antimetabolites; DNA modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Brain cancer; Breast cancer

Most Recent Events

  • 30 Jan 2003 Discontinued - Phase-III for Brain cancer in Canada (IV)
  • 30 Jan 2003 Discontinued - Preregistration for Brain cancer in USA (IV)
  • 30 Jan 2003 Discontinued - Preregistration for Breast cancer diagnosis in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top